<doc>
  <docmeta id="113hr3742ih">
    <bill congress="113" type="hr" number="3742" version="ih"/>
    <revision size="13634" annotations="0" status="complete" id="5" commit-time="2014-01-02T17:34:58Z" committer="mbohmer" doc="113hr3742ih/5.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HA96D6FA4F7714153AE34671499644575" public-private="public">
  <metadata>
<dublinCore>
<dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">113 HR 3742 IH: Antibiotic Development to Advance Patient Treatment Act of 2013</dc:title>
<dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">U.S. House of Representatives</dc:publisher>
<dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-12-12</dc:date>
<dc:format xmlns:dc="http://purl.org/dc/elements/1.1/">text/xml</dc:format>
<dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">EN</dc:language>
<dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code>
    <congress>113th CONGRESS</congress>
    <session>1st Session</session>
    <legis-num>H. R. 3742</legis-num>
    <current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
    <action>
      <action-date date="20131212">December 12, 2013</action-date>
      <action-desc>
        <sponsor name-id="G000550">Mr. Gingrey of Georgia</sponsor> (for himself, <cosponsor name-id="G000410">Mr. Gene Green of Texas</cosponsor>, <cosponsor name-id="S000364">Mr. Shimkus</cosponsor>, <cosponsor name-id="E000215">Ms. Eshoo</cosponsor>, <cosponsor name-id="W000413">Mr. Whitfield</cosponsor>, <cosponsor name-id="D000197">Ms. DeGette</cosponsor>, <cosponsor name-id="B001243">Mrs. Blackburn</cosponsor>, <cosponsor name-id="E000179">Mr. Engel</cosponsor>, <cosponsor name-id="G000568">Mr. Griffith of Virginia</cosponsor>, and <cosponsor name-id="B001251">Mr. Butterfield</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>
      </action-desc>
    </action>
    <legis-type>A BILL</legis-type>
    <official-title>To provide for approval of certain drugs and biological products indicated for use in a limited population of patients in order to address increases in bacterial and fungal resistance to drugs and biological products, and for other purposes.</official-title>
  </form>
  <legis-body id="H944E9726E44E454FA7D41E0238D8F2B7" style="OLC">
    <section id="H90C6D43D99F041C39AC6EBD9172ED895" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the <quote>
          <short-title>Antibiotic Development to Advance Patient Treatment Act of 2013</short-title>
        </quote>.</text>
    </section>
    <section id="H5498C318763C4FDCAAA72D0347A6A56E">
      <enum>2.</enum>
      <header>Approval of certain drugs for use in a limited population of patients</header>
      <subsection id="HFF70DAB6A6ED4F30A2D7F5B99B2A11BA">
        <enum>(a)</enum>
        <header>Approval of certain antibacterial and antifungal drugs</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">Section 505 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/355">
            <cato:entity-ref entity-type="uscode" value="usc/21/355">21 U.S.C. 355</cato:entity-ref>
          </external-xref>)</cato:entity> is amended by adding at the end the following:</text>
        <quoted-block display-inline="no-display-inline" id="HF66A083968874E66BC7BDBEB62FF4DEE" style="OLC">
          <subsection commented="no" id="H201DCCF24EE943A4A9EE9805CE449F56">
            <enum>(x)</enum>
            <header>Approval of certain antibacterial and antifungal drugs for use in a limited population of patients</header>
            <paragraph commented="no" id="HDE48B45E50664C2EA3693A3DB3CF488D">
              <enum>(1)</enum>
              <header>Approval</header>
              <text display-inline="yes-display-inline">At the request of the sponsor of an antibacterial or antifungal drug that is intended to treat a serious or life-threatening disease or condition, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>—</text>
              <subparagraph commented="no" id="H0B3D2493F1824D5D8BEE52181ADBD64E">
                <enum>(A)</enum>
                <text>may approve the drug under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:c">subsection (c)</cato:entity-ref> to treat a limited population of patients for which there is an unmet medical need;</text>
              </subparagraph>
              <subparagraph commented="no" id="H7071094BE5E4492F9E36D2D3B89190F9">
                <enum>(B)</enum>
                <text>in determining whether to grant such approval for a limited population of patients, may rely on traditional endpoints, alternative endpoints, or a combination of traditional and alternative endpoints; datasets of limited size; pharmacologic or pathophysiologic data; data from phase 2 clinical studies; and such other confirmatory evidence as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> deems necessary; and</text>
              </subparagraph>
              <subparagraph commented="no" id="H4059CD46E51A4B8AA97411C80EE1E5E5">
                <enum>(C)</enum>
                <text display-inline="yes-display-inline">shall require the labeling of drugs approved pursuant to this subsection to prominently include in the prescribing information required by <external-xref legal-doc="regulation" parsable-cite="cfr/21/201.57">section 201.57</external-xref> of title 21, Code of Federal Regulations (or any successor regulation) the following statement: <quote>This drug is indicated for use in a limited and specific population of patients.</quote>.</text>
              </subparagraph>
            </paragraph>
            <paragraph commented="no" id="HBD23012930474F779FC2B3151C62791C">
              <enum>(2)</enum>
              <header>Promotional materials</header>
              <text display-inline="yes-display-inline">The provisions of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:506/ss:c/p:2/sp:B">section 506(c)(2)(B)</cato:entity-ref> shall apply with respect to approval under this subsection to the same extent and in the same manner as such provisions apply with respect to accelerated approval under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:506/ss:c/p:1">section 506(c)(1)</cato:entity-ref>.</text>
            </paragraph>
            <paragraph id="HD8698890DA47492DBAE78AFA2870A399">
              <enum>(3)</enum>
              <header>Withdrawal of limited population approval requirements</header>
              <text display-inline="yes-display-inline">If a drug is approved pursuant to this subsection to treat a limited population of patients and is subsequently approved or licensed under this section or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public Health Service Act</cato:entity-ref>, respectively, without such a limitation, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may remove any labeling requirements or postmarketing conditions made applicable to the drug during the earlier approval process.</text>
            </paragraph>
            <paragraph id="H71DE12882BEC4CB49DD8D51696FD7354">
              <enum>(4)</enum>
              <header>Relation to other provisions</header>
              <text>Nothing in this subsection shall be construed to prohibit designation and expedited review of a drug as a breakthrough therapy under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:506/ss:a">section 506(a)</cato:entity-ref>, designation and treatment of a drug as a fast track product under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:506/ss:b">section 506(b)</cato:entity-ref>, or accelerated approval of the drug under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:506/ss:c">section 506(c)</cato:entity-ref>, in combination with approval of the drug for use in a limited population of patients under this subsection.</text>
            </paragraph>
            <paragraph id="H041CAE1F8B4B4456A64812759A0F0941">
              <enum>(5)</enum>
              <header>Rule of construction</header>
              <text display-inline="yes-display-inline">Nothing in this subsection shall be construed to alter the standards of evidence under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:c">subsection (c)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:d">(d)</cato:entity-ref> (including the substantial evidence standard in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:d">subsection (d)</cato:entity-ref>). <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:c">Subsections (c)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:d">(d)</cato:entity-ref> and such standards of evidence apply to the review and approval of drugs under this subsection, including whether a drug is safe and effective. Nothing in this subsection shall be construed to limit the authority of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> to approve products pursuant to this Act and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act">Public Health Service Act</cato:entity-ref> as authorized prior to the date of enactment of this subsection.</text>
            </paragraph>
            <paragraph id="HB3AC1941B1714721AB6DB2FFB968C8BB">
              <enum>(6)</enum>
              <header>Effective immediately</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall have the authorities vested in the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> by this subsection beginning on the date of enactment of this subsection, irrespective of when and whether the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> promulgates final regulations to carry out this subsection.</text>
            </paragraph>
          </subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
      </subsection>
      <subsection id="HAAB93BF856994C39A5CFC9A084CFB0B1">
        <enum>(b)</enum>
        <header>Licensure of certain biological products</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Public Health Service Act/s:351/ss:j">Section 351(j) of the Public Health Service Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/262">
            <cato:entity-ref entity-type="uscode" value="usc/42/262/j">42 U.S.C. 262(j)</cato:entity-ref>
          </external-xref>)</cato:entity> is amended—</text>
        <paragraph id="HD7D95EAC6DBB45D9BDF62DD802CD85F1">
          <enum>(1)</enum>
          <text>by striking <quote>(j)</quote> and inserting <quote>(j)(1)</quote>;</text>
        </paragraph>
        <paragraph id="H7335DB92B4CD4741A4EB8F1EF80B364F">
          <enum>(2)</enum>
          <text>by inserting <quote>
              <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:x" proposed="true">505(x)</cato:entity-ref>,</quote> after <quote>505(p),</quote>; and</text>
        </paragraph>
        <paragraph id="H72E1E5676FC04ED986635C45A4994C16">
          <enum>(3)</enum>
          <text>by adding at the end the following:</text>
          <quoted-block display-inline="no-display-inline" id="HA3A60261C55C469D8AF10076275CA27E" style="OLC">
            <paragraph id="HFF134B0702874AE3B0FEADD8083D9838">
              <enum>(2)</enum>
              <text display-inline="yes-display-inline">In applying <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:x" proposed="true">section 505(x) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> to the licensure of biological products under this section—</text>
              <subparagraph id="H75697B89377E45E19787EFEC7114ACB2">
                <enum>(A)</enum>
                <text display-inline="yes-display-inline">references to an antibacterial or antifungal drug that is intended to treat a serious or life-threatening disease or condition shall be construed to refer to biological products intended to treat a bacterial or fungal infection associated with a serious or life-threatening disease; and</text>
              </subparagraph>
              <subparagraph id="H991EAB9ABA52459981EBB4C78C56CBB9">
                <enum>(B)</enum>
                <text>references to approval of a drug under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:c">section 505(c) of such Act</cato:entity-ref> shall be construed to refer to licensure of a biological product under subsection (a) of this section.</text>
              </subparagraph>
            </paragraph>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
        </paragraph>
      </subsection>
      <subsection id="H95341D8CCC054822833D75E04C65693F">
        <enum>(c)</enum>
        <header>Monitoring</header>
        <text>
          <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/t:III">Title III of the Public Health Service Act</cato:entity-ref> is amended by inserting after <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Public Health Service Act/s:317T">section 317T</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/247b-22">
            <cato:entity-ref entity-type="uscode" value="usc/42/247b–22">42 U.S.C. 247b–22</cato:entity-ref>
            </external-xref>)</cato:entity> the following:</text>
        <quoted-block display-inline="no-display-inline" id="HF4A9C8CE94D44192BD8900E06BA9384A" style="OLC">
          <section id="H2DBC4188EEAF4D5C95DF58BADB8491E9">
            <enum>317U.</enum>
            <header>Monitoring antibacterial and antifungal drug use and resistance</header>
            <subsection id="H1B716AE616FF49C386FFBA4B34CF7286">
              <enum>(a)</enum>
              <header>Monitoring</header>
              <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, acting through the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Director of the Centers for Disease Control and Prevention</cato:entity-ref>, shall use the National Healthcare Safety Network or another appropriate monitoring system to monitor—</text>
              <paragraph id="HA22BC24585024B8C93C2AE77E1C15FB4">
                <enum>(1)</enum>
                <text>the use of antibacterial and antifungal drugs, including those receiving approval or licensure for a limited population pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:x" proposed="true">section 505(x) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>; and</text>
              </paragraph>
              <paragraph id="H9029ACA5E2974CDCB15078452FCBA3EE">
                <enum>(2)</enum>
                <text>changes in bacterial and fungal resistance to drugs.</text>
              </paragraph>
            </subsection>
            <subsection id="H191DD5153E4A4CFD839ED293A15CE6EB">
              <enum>(b)</enum>
              <header>Public availability of data</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, acting through the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Director of the Centers for Disease Control and Prevention</cato:entity-ref>, shall make the data derived from monitoring under this section publicly available for the purposes of—</text>
              <paragraph id="H2C9EF6282D034DFCB97E94156B169E74">
                <enum>(1)</enum>
                <text>improving the monitoring of important trends in antibacterial and antifungal resistance; and</text>
              </paragraph>
              <paragraph id="H50C5153AE69A463ABCD051E36A1ACB43">
                <enum>(2)</enum>
                <text display-inline="yes-display-inline">ensuring appropriate stewardship of antibacterial and antifungal drugs, including those receiving approval or licensure for a limited population pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:x" proposed="true">section 505(x) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>.</text>
              </paragraph>
            </subsection>
          </section>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
      </subsection>
    </section>
    <section id="H4F0C70A5D35F4D7BB6DB1590DE05FDDA">
      <enum>3.</enum>
      <header>Susceptibility test interpretive criteria for microbial organisms</header>
      <subsection id="HCED63DACFC4341F6A609ADBA31A9BF20">
        <enum>(a)</enum>
        <header>In general</header>
        <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:511">Section 511 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/360a">
            <cato:entity-ref entity-type="uscode" value="usc/21/360a">21 U.S.C. 360a</cato:entity-ref>
          </external-xref>)</cato:entity> is amended to read as follows:</text>
        <quoted-block id="HBF84DA49E70A46219662CD674C3BE2D4" style="OLC">
          <section id="HB372BAD007344198BD105764ECC0AD3A">
            <enum>511.</enum>
            <header>Susceptibility test interpretive criteria for microbial organisms</header>
            <subsection id="H7EDED925B6874A6DB07F291E22B9CD59">
              <enum>(a)</enum>
              <header>In general</header>
              <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall identify upon approval and subsequently update susceptibility test interpretive criteria for antibacterial drugs (including biological products intended to treat a bacterial infection and other types of antimicrobial drugs, as deemed appropriate by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>), including qualified infectious disease products, by relying upon, to the extent available—</text>
              <paragraph id="H9CE3783438DD49A5A84998A9D66228EA">
                <enum>(1)</enum>
                <text>preclinical and clinical data, including pharmacokinetic, pharmacodynamic, and epidemiological data;</text>
              </paragraph>
              <paragraph id="HDB425A38608A47C1BB94109A107001F4">
                <enum>(2)</enum>
                <text>Bayesian and pharmacometric statistical methodologies; and</text>
              </paragraph>
              <paragraph id="H8DDD2B2A955A4C33991BCD76CAA2536E">
                <enum>(3)</enum>
                <text>such other confirmatory evidence as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> deems necessary.</text>
              </paragraph>
            </subsection>
            <subsection id="HF90A5A9199A247C5960CC5727D962CD5">
              <enum>(b)</enum>
              <header>Responding to susceptibility test interpretive criteria identified or updated by private entities</header>
              <paragraph id="HA8213E5DBAB64DD8AC8A37F603FA00DC">
                <enum>(1)</enum>
                <header>In general</header>
                <text>Each quarter of each fiscal year, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall—</text>
                <subparagraph id="H4F1A0A93EE7143E5B4573E26B55D948F">
                  <enum>(A)</enum>
                  <text>evaluate any appropriate new or updated susceptibility test interpretive criteria published by a nationally or internationally recognized standard development organization; and</text>
                </subparagraph>
                <subparagraph id="H414642BEDB7E49A883D45D7D8140A3F7">
                  <enum>(B)</enum>
                  <text>publish on the public Website of the Food and Drug Administration a notice—</text>
                  <clause id="H1E9C3BDA08DF4439BF731C5D5CEA6039">
                    <enum>(i)</enum>
                    <text>adopting the new or updated interpretive criteria;</text>
                  </clause>
                  <clause id="HB8CC378D44BF47C3820055135FAC38F0">
                    <enum>(ii)</enum>
                    <text>declining to adopt the new or updated interpretive criteria and explaining the reason for such decision; or</text>
                  </clause>
                  <clause id="H59886C120A5849758D8C6CEF704B28CC">
                    <enum>(iii)</enum>
                    <text>adopting one or more parts of the new or updated interpretive criteria, declining to adopt the remainder of such criteria, and explaining the reason for so declining.</text>
                  </clause>
                </subparagraph>
              </paragraph>
              <paragraph id="HB67F65FE122F418A82665C58C4417E96">
                <enum>(2)</enum>
                <header>Annual compilation of notices</header>
                <text>Each year, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall compile the notices published under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:511/ss:b/p:1/sp:B" proposed="true">paragraph (1)(B)</cato:entity-ref> and publish such compilation in the Federal Register.</text>
              </paragraph>
              <paragraph id="H0D6DBEE65434409596E658B7C75C1498">
                <enum>(3)</enum>
                <header>Relation to section 514(<enum-in-header>c</enum-in-header>)</header>
                <text display-inline="yes-display-inline">Any susceptibility test interpretive criterion for which an approval is in effect under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:511/ss:b/p:1" proposed="true">paragraph (1)</cato:entity-ref> may be recognized as a standard by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:514/ss:c/p:1">section 514(c)(1)</cato:entity-ref>.</text>
              </paragraph>
              <paragraph id="H8C9B4D4DA9CA4B44A573B0D09487AD94">
                <enum>(4)</enum>
                <header>Use of non-adopted criteria</header>
                <text>Nothing in this section prohibits the sponsor of a drug or device from seeking approval or clearance of the drug or device, or changes to the drug, the device, or its labeling, on the basis of susceptibility test interpretive criteria which differ from those adopted pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:511/ss:b/p:1" proposed="true">paragraph (1)</cato:entity-ref>.</text>
              </paragraph>
            </subsection>
            <subsection id="H6796C111B31447D2AFF43F8DE7400E26">
              <enum>(c)</enum>
              <header>Definitions</header>
              <text>In this section:</text>
              <paragraph commented="no" id="H0460DFCC9D7A4669B2452CD434F441CD">
                <enum>(1)</enum>
                <text>The term <term>qualified infectious disease product</term> means a qualified infectious disease product designated under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505E/ss:d">505E(d)</cato:entity-ref>.</text>
              </paragraph>
              <paragraph id="H11C96BE61161481183D378CF60EF53A4">
                <enum>(2)</enum>
                <text display-inline="yes-display-inline">The term <term>susceptibility test interpretive criteria</term> means one or more specific values which characterize the degree to which bacteria or other microbes are resistant to the drug (or drugs) tested, such as clinically susceptible, intermediate, or resistant.</text>
              </paragraph>
            </subsection>
          </section>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
      </subsection>
      <subsection id="H52CE128312614A9E8D34409CDDCDC283">
        <enum>(b)</enum>
        <header>Conforming amendment</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Food and Drug Administration Amendments Act of 2007/s:1111">Section 1111 of the Food and Drug Administration Amendments Act of 2007</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/42/247d–5a">42 U.S.C. 247d–5a</cato:entity-ref>;</cato:entity> relating to identification of clinically susceptible concentrations of antimicrobials) is repealed.</text>
      </subsection>
      <subsection id="HDD045620DA5844D28FFC6571EF74B94F">
        <enum>(c)</enum>
        <header>Report to Congress</header>
        <text display-inline="yes-display-inline">Not later than one year after the date of enactment of this Act, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary of Health and Human Services</cato:entity-ref> shall submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on Energy and Commerce of the House of Representatives</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on Health, Education, Labor, and Pensions of the Senate</cato:entity-ref> a report on the progress made in implementing <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:511" proposed="true">section 511 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/360a">
            <cato:entity-ref entity-type="uscode" value="usc/21/360a" proposed="true">21 U.S.C. 360a</cato:entity-ref>
          </external-xref>)</cato:entity>, as amended by this section.</text>
      </subsection>
    </section>
    <section commented="no" id="H78CD432938E345DBAA74C1BABBDC1CB5">
      <enum>4.</enum>
      <header>No effect on health care practice</header>
      <text display-inline="no-display-inline">Nothing in the <short-title>
          <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Antibiotic Development to Advance Patient Treatment Act of 2013" proposed="true">Antibiotic Development to Advance Patient Treatment Act of 2013</cato:entity-ref>
        </short-title> (including the amendments made thereby) shall be construed to restrict, in any manner, the prescribing of antibiotics or other products by health care professionals, or to limit the practice of health care.</text>
    </section>
  </legis-body>
</bill>
</doc>